<p>Elanco Animal Health（紐約證券交易所代碼：ELAN - 獲取免費報告）在週四發佈的一份報告中，摩根大通的股票研究人員將其目標價格從 28.00 美元上調至 30.00 美元，Benzinga 報道。該券商目前對該股票給予 “增持” 評級。摩根大通的目標價格表明，相較於公司之前的收盤價，存在 25.03% 的潛在上漲空間。</p>
<p>獲取 <strong>Elanco Animal Health</strong> 的提醒：</p>
<ul>
<li>看漲還是看跌？評估動物健康護理股票</li>
</ul>
<p>其他一些研究分析師最近也對該公司發佈了報告。花旗集團在 4 月 15 日的報告中開始覆蓋 Elanco Animal Health。他們對該股票設定了 “買入” 評級和 30.00 美元的目標價格。KeyCorp 在 2 月 25 日的報告中將 Elanco Animal Health 的目標價格從 27.00 美元上調至 29.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 4 月 27 日的報告中將 Elanco Animal Health 的評級從 “賣出（d）” 上調至 “賣出（d+）”。瑞銀集團在 3 月 10 日的研究報告中重申了對 Elanco Animal Health 股票的 “買入” 評級。最後，Piper Sandler 在 1 月 22 日的研究報告中將 Elanco Animal Health 的評級從 “中性” 上調至 “增持”，並將其目標價格從 24.00 美元上調至 30.00 美元。一位股票研究分析師給予該股票 “強烈買入” 評級，九位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價格為 28.10 美元。</p>
<p><strong>閲讀我們關於 Elanco Animal Health 的最新研究報告</strong></p>
<h2>Elanco Animal Health 股票下跌 8.3%</h2>
<ul>
<li>Zoetis 宣佈新股息，暗示被低估</li>
</ul>
<p>在週四的交易時段，NYSE:ELAN 下跌 2.19 美元，達到 24.00 美元。該公司交易了 8,155,888 股，相較於其平均交易量 5,021,183 股。該公司的 50 日移動平均價格為 23.85 美元，200 日移動平均價格為 23.33 美元。該股票的市值為 119.3 億美元，市盈率為-50.20，市盈增長比率為 2.93，貝塔值為 1.69。Elanco Animal Health 的 1 年最低價為 11.83 美元，1 年最高價為 27.72 美元。該公司的流動比率為 2.17，速動比率為 1.08，債務與股本比率為 0.60。</p>
<p>Elanco Animal Health（紐約證券交易所代碼：ELAN - 獲取免費報告）最後一次公佈季度財報是在 5 月 6 日。該公司報告本季度每股收益（EPS）為 0.40 美元，超出分析師一致預期的 0.34 美元，超出幅度為 0.06 美元。該公司本季度的收入為 13.7 億美元，而一致預期為 12.8 億美元。Elanco Animal Health 的股本回報率為 7.16%，淨利潤率為-4.92%。該公司的季度收入同比增長 14.9%。在去年同期，該公司每股收益為 0.37 美元。Elanco Animal Health 已將其 2026 年第二季度的指導目標設定為 0.250-0.285 EPS，2026 財年的指導目標設定為 1.030-1.090 EPS。分析師預測 Elanco Animal Health 在當前年度的每股收益為 1.03 美元。</p>
<h2>對 Elanco Animal Health 的對沖基金看法</h2>
<ul>
<li>2 只具有重大上漲潛力的逆向股票選擇</li>
</ul>
<p>對沖基金最近對該公司的持倉進行了調整。瑞銀集團在第三季度將其在 Elanco Animal Health 的持股增加了 56.7%。瑞銀集團目前擁有 16,468,148 股該公司股票，價值 331,669,000 美元，此前在上個季度又購買了 5,961,457 股。T. Rowe Price Investment Management Inc.在第四季度將其在 Elanco Animal Health 的持股增加了 11.8%。T. Rowe Price Investment Management Inc.目前擁有 35,227,418 股該公司股票，價值 797,197,000 美元，此前在上個季度又購買了 3,717,404 股。Invesco Ltd.在第四季度將其在 Elanco Animal Health 的持股增加了 336.0%。Invesco Ltd.目前擁有 4,789,037 股該公司股票，價值 108,376,000 美元，此前在上個季度又購買了 3,690,735 股。Allspring Global Investments Holdings LLC 在第一季度購買了 Elanco Animal Health 的新頭寸，價值約 66,390,000 美元。最後，Artemis Investment Management LLP 在第四季度購買了 Elanco Animal Health 的新頭寸，價值約 55,693,000 美元。機構投資者持有該公司 97.48% 的股票。</p>
<h2>影響 Elanco Animal Health 的關鍵故事</h2>
<p>以下是本週影響 Elanco Animal Health 的關鍵新聞故事：</p>
<ul>
<li>積極情緒：季度業績超預期 — Elanco 報告 Q1 調整後每股收益為 $0.40（對比 $0.34 的市場預期），收入為 $13.71 億美元（同比增長 15%；有機增長 10%），調整後 EBITDA 為 $3.34 億美元，利潤率改善。這些結果驗證了公司的創新驅動增長。Elanco Animal Health 報告 2026 年第一季度業績</li>
<li>積極情緒：上調全年目標 — Elanco 上調了 2026 財年的指引（收入目標為 $50.10 億至 $50.85 億，調整後 EBITDA 為 $9.75 億至 $10.05 億，調整後每股收益為 $1.03 至 $1.09），並將創新收入目標提高至 $12 億；管理層還收緊了年末淨槓桿目標至 ~3.0–3.2 倍。這些提升支持未來的盈利增長。Elanco Animal Health 報告 2026 年第一季度業績</li>
<li>積極情緒：監管/產品勢頭 — 公司宣佈了 Negasunt Powder 和 Tanidil 的緊急使用授權，支持近期的產品收入和投資者重視的管道證明點。Elanco Animal Health 在盈利強勁和產品勢頭下上漲</li>
<li>中性情緒：盈利材料可用 — 完整的盈利電話會議記錄和投資者演示文稿/幻燈片已發佈（對細分市場、地理和利潤驅動因素的詳細信息很有用）。Elanco 2026 年第一季度盈利電話會議記錄 Q1 結果 - 盈利電話會議演示</li>
<li>消極情緒：Q2 指引略低於市場預期 — Elanco 指引 Q2 每股收益為 $0.250–$0.285，而市場預期接近 $0.29（收入大致持平）。中間值的失誤可能削弱了近期的預期，並導致在反彈後出現獲利回吐。Elanco Animal Health 報告 2026 年第一季度業績</li>
</ul>
<h2>關於 Elanco Animal Health</h2>
<p>(獲取免費報告)</p>
<p>Elanco Animal Health Inc 是全球動物健康領域的領導者，致力於改善食品和伴侶動物的福祉。該公司開發、製造和銷售一系列產品，包括寄生蟲藥、疫苗、抗生素和飼料添加劑，旨在預防和治療家畜和寵物的疾病。Elanco 的產品組合涵蓋了食品生產動物——如牛、豬、家禽和水產養殖——以及伴侶動物，提供支持寄生蟲控制、疼痛管理和傳染病預防的產品。</p>
<p>Elanco 最初成立於 20 世紀中期，作為禮來公司（Eli Lilly and Company）的動物健康部門，2018 年獨立成為一家上市公司。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Elanco Animal Health</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Elanco Animal Health 嗎？</h2>
<p>在你考慮 Elanco Animal Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Elanco Animal Health 並不在名單上。</p>
<p>雖然 Elanco Animal Health 目前在分析師中獲得中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ELAN

<p>摩根大通已將 Elanco Animal Health（紐約證券交易所代碼：ELAN）的目標股價從 28.00 美元上調至 30.00 美元，維持 “增持” 評級。這個新目標暗示相較於前一交易日收盤價有 25.03% 的潛在上漲空間。其他分析師也給予了積極評級，平均評級為 “適度買入”，目標股價為 28.10 美元。儘管 Elanco 最近公佈了強勁的季度財報，顯示每股收益為 0.40 美元，超出預期，但其股價最近交易下跌至 24.00 美元。機構投資者持有該公司 97.48% 的股份</p>

<p>Elanco Animal Health (NYSE:ELAN - Get Free Report) had its price target increased by equities researchers at JPMorgan Chase &amp; Co. from $28.00 to $30.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target indicates a potential upside of 25.03% from the company's previous close.</p>
<div class="lb-trans"><p>Elanco Animal Health（紐約證券交易所代碼：ELAN - 獲取免費報告）在週四發佈的一份報告中，摩根大通的股票研究人員將其目標價格從 28.00 美元上調至 30.00 美元，Benzinga 報道。該券商目前對該股票給予 “增持” 評級。摩根大通的目標價格表明，相較於公司之前的收盤價，存在 25.03% 的潛在上漲空間。</p>
</div><p>Get <strong>Elanco Animal Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Elanco Animal Health</strong> 的提醒：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看漲還是看跌？評估動物健康護理股票</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on the company. Citigroup initiated coverage on Elanco Animal Health in a report on Wednesday, April 15th. They set a &#34;buy&#34; rating and a $30.00 price target on the stock. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, February 25th. Weiss Ratings raised Elanco Animal Health from a &#34;sell (d)&#34; rating to a &#34;sell (d+)&#34; rating in a report on Monday, April 27th. UBS Group restated a &#34;buy&#34; rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Piper Sandler upgraded Elanco Animal Health from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and upped their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $28.10.</p>
<div class="lb-trans"><p>其他一些研究分析師最近也對該公司發佈了報告。花旗集團在 4 月 15 日的報告中開始覆蓋 Elanco Animal Health。他們對該股票設定了 “買入” 評級和 30.00 美元的目標價格。KeyCorp 在 2 月 25 日的報告中將 Elanco Animal Health 的目標價格從 27.00 美元上調至 29.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 4 月 27 日的報告中將 Elanco Animal Health 的評級從 “賣出（d）” 上調至 “賣出（d+）”。瑞銀集團在 3 月 10 日的研究報告中重申了對 Elanco Animal Health 股票的 “買入” 評級。最後，Piper Sandler 在 1 月 22 日的研究報告中將 Elanco Animal Health 的評級從 “中性” 上調至 “增持”，並將其目標價格從 24.00 美元上調至 30.00 美元。一位股票研究分析師給予該股票 “強烈買入” 評級，九位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價格為 28.10 美元。</p>
</div><p><strong>Read Our Latest Research Report on Elanco Animal Health</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Elanco Animal Health 的最新研究報告</strong></p>
</div><h2>Elanco Animal Health Stock Down 8.3%</h2>
<div class="lb-trans"><h2>Elanco Animal Health 股票下跌 8.3%</h2>
</div><ul>
<li>Zoetis Declares New Dividend, Hinting At Undervaluation</li>
</ul>
<div class="lb-trans"><ul>
<li>Zoetis 宣佈新股息，暗示被低估</li>
</ul>
</div><p>NYSE:ELAN traded down $2.19 during trading hours on Thursday, reaching $24.00. 8,155,888 shares of the company traded hands, compared to its average volume of 5,021,183. The business's 50-day moving average price is $23.85 and its two-hundred day moving average price is $23.33. The stock has a market capitalization of $11.93 billion, a P/E ratio of -50.20, a P/E/G ratio of 2.93 and a beta of 1.69. Elanco Animal Health has a 1 year low of $11.83 and a 1 year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60.</p>
<div class="lb-trans"><p>在週四的交易時段，NYSE:ELAN 下跌 2.19 美元，達到 24.00 美元。該公司交易了 8,155,888 股，相較於其平均交易量 5,021,183 股。該公司的 50 日移動平均價格為 23.85 美元，200 日移動平均價格為 23.33 美元。該股票的市值為 119.3 億美元，市盈率為-50.20，市盈增長比率為 2.93，貝塔值為 1.69。Elanco Animal Health 的 1 年最低價為 11.83 美元，1 年最高價為 27.72 美元。該公司的流動比率為 2.17，速動比率為 1.08，債務與股本比率為 0.60。</p>
</div><p>Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts predict that Elanco Animal Health will post 1.03 earnings per share for the current year.</p>
<div class="lb-trans"><p>Elanco Animal Health（紐約證券交易所代碼：ELAN - 獲取免費報告）最後一次公佈季度財報是在 5 月 6 日。該公司報告本季度每股收益（EPS）為 0.40 美元，超出分析師一致預期的 0.34 美元，超出幅度為 0.06 美元。該公司本季度的收入為 13.7 億美元，而一致預期為 12.8 億美元。Elanco Animal Health 的股本回報率為 7.16%，淨利潤率為-4.92%。該公司的季度收入同比增長 14.9%。在去年同期，該公司每股收益為 0.37 美元。Elanco Animal Health 已將其 2026 年第二季度的指導目標設定為 0.250-0.285 EPS，2026 財年的指導目標設定為 1.030-1.090 EPS。分析師預測 Elanco Animal Health 在當前年度的每股收益為 1.03 美元。</p>
</div><h2>Hedge Funds Weigh In On Elanco Animal Health</h2>
<div class="lb-trans"><h2>對 Elanco Animal Health 的對沖基金看法</h2>
</div><ul>
<li>2 Contrarian Stock Picks With Major Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只具有重大上漲潛力的逆向股票選擇</li>
</ul>
</div><p>Hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Invesco Ltd. boosted its stake in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company's stock valued at $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Elanco Animal Health during the first quarter valued at approximately $66,390,000. Finally, Artemis Investment Management LLP bought a new position in Elanco Animal Health during the fourth quarter valued at approximately $55,693,000. Institutional investors own 97.48% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近對該公司的持倉進行了調整。瑞銀集團在第三季度將其在 Elanco Animal Health 的持股增加了 56.7%。瑞銀集團目前擁有 16,468,148 股該公司股票，價值 331,669,000 美元，此前在上個季度又購買了 5,961,457 股。T. Rowe Price Investment Management Inc.在第四季度將其在 Elanco Animal Health 的持股增加了 11.8%。T. Rowe Price Investment Management Inc.目前擁有 35,227,418 股該公司股票，價值 797,197,000 美元，此前在上個季度又購買了 3,717,404 股。Invesco Ltd.在第四季度將其在 Elanco Animal Health 的持股增加了 336.0%。Invesco Ltd.目前擁有 4,789,037 股該公司股票，價值 108,376,000 美元，此前在上個季度又購買了 3,690,735 股。Allspring Global Investments Holdings LLC 在第一季度購買了 Elanco Animal Health 的新頭寸，價值約 66,390,000 美元。最後，Artemis Investment Management LLP 在第四季度購買了 Elanco Animal Health 的新頭寸，價值約 55,693,000 美元。機構投資者持有該公司 97.48% 的股票。</p>
</div><h2>Key Stories Impacting Elanco Animal Health</h2>
<div class="lb-trans"><h2>影響 Elanco Animal Health 的關鍵故事</h2>
</div><p>Here are the key news stories impacting Elanco Animal Health this week:</p>
<div class="lb-trans"><p>以下是本週影響 Elanco Animal Health 的關鍵新聞故事：</p>
</div><ul>
<li>Positive Sentiment: Quarterly beat — Elanco reported Q1 adjusted EPS of $0.40 (vs. $0.34 consensus) and revenue of $1.371B (+15% YoY; 10% organic), with adjusted EBITDA of $334M and improving margins. These results validate the company’s innovation-led growth. Elanco Animal Health Reports First Quarter 2026 Results</li>
<li>Positive Sentiment: Upgraded full-year targets — Elanco raised FY2026 guidance (revenue to $5.010B–$5.085B, adjusted EBITDA to $975M–$1,005M, adjusted EPS to $1.03–$1.09) and raised its innovation revenue target to $1.2B; management also tightened year-end net leverage goals to ~3.0–3.2x. These lifts are supportive of forward earnings growth. Elanco Animal Health Reports First Quarter 2026 Results</li>
<li>Positive Sentiment: Regulatory/product momentum — The company announced emergency use authorizations for Negasunt Powder and Tanidil, supporting near-term product revenue and pipeline proof points that investors value. Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum</li>
<li>Neutral Sentiment: Earnings materials available — Full earnings call transcript and the investor presentation/slide deck were released (useful for details on segments, geography and margin drivers). Elanco Q1 2026 Earnings Call TranscriptQ1 Results - Earnings Call Presentation</li>
<li>Negative Sentiment: Q2 guide slightly soft vs. consensus — Elanco guided Q2 EPS to $0.250–$0.285 vs. a consensus near $0.29 (revenues roughly in line). That miss on the midpoint may have trimmed near-term expectations and contributed to profit-taking after the rally. Elanco Animal Health Reports First Quarter 2026 Results</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：季度業績超預期 — Elanco 報告 Q1 調整後每股收益為 $0.40（對比 $0.34 的市場預期），收入為 $13.71 億美元（同比增長 15%；有機增長 10%），調整後 EBITDA 為 $3.34 億美元，利潤率改善。這些結果驗證了公司的創新驅動增長。Elanco Animal Health 報告 2026 年第一季度業績</li>
<li>積極情緒：上調全年目標 — Elanco 上調了 2026 財年的指引（收入目標為 $50.10 億至 $50.85 億，調整後 EBITDA 為 $9.75 億至 $10.05 億，調整後每股收益為 $1.03 至 $1.09），並將創新收入目標提高至 $12 億；管理層還收緊了年末淨槓桿目標至 ~3.0–3.2 倍。這些提升支持未來的盈利增長。Elanco Animal Health 報告 2026 年第一季度業績</li>
<li>積極情緒：監管/產品勢頭 — 公司宣佈了 Negasunt Powder 和 Tanidil 的緊急使用授權，支持近期的產品收入和投資者重視的管道證明點。Elanco Animal Health 在盈利強勁和產品勢頭下上漲</li>
<li>中性情緒：盈利材料可用 — 完整的盈利電話會議記錄和投資者演示文稿/幻燈片已發佈（對細分市場、地理和利潤驅動因素的詳細信息很有用）。Elanco 2026 年第一季度盈利電話會議記錄 Q1 結果 - 盈利電話會議演示</li>
<li>消極情緒：Q2 指引略低於市場預期 — Elanco 指引 Q2 每股收益為 $0.250–$0.285，而市場預期接近 $0.29（收入大致持平）。中間值的失誤可能削弱了近期的預期，並導致在反彈後出現獲利回吐。Elanco Animal Health 報告 2026 年第一季度業績</li>
</ul>
</div><h2>About Elanco Animal Health</h2>
<div class="lb-trans"><h2>關於 Elanco Animal Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.</p>
<div class="lb-trans"><p>Elanco Animal Health Inc 是全球動物健康領域的領導者，致力於改善食品和伴侶動物的福祉。該公司開發、製造和銷售一系列產品，包括寄生蟲藥、疫苗、抗生素和飼料添加劑，旨在預防和治療家畜和寵物的疾病。Elanco 的產品組合涵蓋了食品生產動物——如牛、豬、家禽和水產養殖——以及伴侶動物，提供支持寄生蟲控制、疼痛管理和傳染病預防的產品。</p>
</div><p>Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.</p>
<div class="lb-trans"><p>Elanco 最初成立於 20 世紀中期，作為禮來公司（Eli Lilly and Company）的動物健康部門，2018 年獨立成為一家上市公司。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Elanco Animal Health</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Elanco Animal Health</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=ELAN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Elanco Animal Health 嗎？</h2>
</div><p>Before you consider Elanco Animal Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Elanco Animal Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Elanco Animal Health 並不在名單上。</p>
</div><p>While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Elanco Animal Health 目前在分析師中獲得中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at JPMorgan Chase & Co.

Market Beat

Elanco Animal Health

摩根大通

花旗

科凱國際

瑞銀集團

Piper Sandler Cos

碩騰

普信金融

景順投資管理

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

摩根大通給予 Elanco Animal Health（紐約證券交易所代碼：ELAN）新的目標價為 30.00 美元